Maxim raises price target to $23?, page-15

Regenxbio (NASDAQ:RGNX) turned in a strong performance Wednesday, with an upsized initial public offering that raised $138.6 million.

Regenexbio is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases.

Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.

REGENXBIO’s foundation is our proprietary recombinant adeno-associated virus (AAV) gene delivery platform – our NAV Technology Platform – which consists of exclusive rights to more than 100 novel AAV serotypes, including AAV7, AAV8, AAV9 and AAVrh10. Our NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed product candidates and 18 partnered product candidates developed by our NAV Technology Licensees. Most of our NAV Technology Licensees have licensed specific vectors (NAV Vectors) from our NAV Technology Platform for the indications they are pursuing.

So its platform is being applied to 23 development products and has over a 100 patents. Sorry you just can't make a comparison between the two in my opinion.